SPBC36.02c Antibody

What is SPBC36.02c and why is it significant in fission yeast research?

SPBC36.02c is a protein found in Schizosaccharomyces pombe (fission yeast), a model organism widely used in molecular and cellular biology research. The antibody against this protein is significant because it allows researchers to study protein expression, localization, and function in this important model organism. Fission yeast serves as an excellent model for studying basic cellular processes like cell division, DNA replication, and gene expression due to its similarity to higher eukaryotes while maintaining experimental simplicity . When designing experiments with this antibody, researchers should consider the evolutionary conservation of SPBC36.02c and its potential homologs in other species if comparative studies are planned.

What detection methods are validated for the SPBC36.02c antibody?

The SPBC36.02c antibody has been validated for enzyme-linked immunosorbent assay (ELISA) and Western blot (WB) applications . These techniques enable researchers to detect and quantify the protein in various experimental contexts. For Western blot applications, the antibody can be used to identify the protein based on molecular weight, while ELISA allows for quantitative analysis in solution. When implementing these methods, researchers should include appropriate positive and negative controls to ensure specificity and validate results, particularly when working with complex protein mixtures from yeast lysates.

How should SPBC36.02c antibody be stored to maintain its activity?

For optimal performance, store the SPBC36.02c antibody at -20°C or -80°C upon receipt. The antibody is supplied in liquid form with a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative . Avoid repeated freeze-thaw cycles as they can degrade antibody performance. If frequent usage is anticipated, consider preparing working aliquots to minimize freeze-thaw cycles. The glycerol in the storage buffer helps prevent freezing damage and maintains stability during storage.

What are the optimal sample preparation methods for detecting SPBC36.02c in fission yeast?

For optimal sample preparation when working with SPBC36.02c in fission yeast, researchers should consider the following methodological approach:

• Cell lysis: Use glass bead disruption in cold lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100) supplemented with protease inhibitors.

• Clearing: Centrifuge lysates at high speed (>14,000 × g) for 15 minutes at 4°C to remove cell debris.

• Protein quantification: Determine protein concentration using Bradford or BCA assay.

• Sample denaturation: For Western blotting, denature samples in Laemmli buffer at 95°C for 5 minutes.

• Loading controls: Include appropriate loading controls such as anti-tubulin or anti-actin antibodies.

This preparation methodology ensures consistent results while preserving protein integrity and reactivity with the antibody. For co-immunoprecipitation applications, milder lysis conditions might be preferable to maintain protein-protein interactions.

How can cross-reactivity issues be addressed when using SPBC36.02c antibody?

Cross-reactivity is a critical consideration when working with antibodies. For SPBC36.02c antibody:

• Perform pre-adsorption: Incubate the antibody with non-target proteins or lysates from knockout strains lacking SPBC36.02c to remove non-specific antibodies.

• Include multiple controls: Always include wild-type, knockout, and overexpression samples when possible.

• Optimize antibody dilution: Titrate antibody concentrations to find the optimal signal-to-noise ratio.

• Blocking optimization: Test different blocking agents (BSA, non-fat milk, commercial blockers) to reduce background.

• Validation with alternative techniques: Confirm findings with orthogonal methods like mass spectrometry.

These approaches reflect similar methodologies used in antibody specificity assessment as described for other research antibodies, where careful evaluation of binding modes and cross-reactivity patterns is essential .

What is the recommended protocol for immunofluorescence using SPBC36.02c antibody?

While the SPBC36.02c antibody hasn't been specifically validated for immunofluorescence, researchers interested in this application could adapt protocols used for similar yeast antibodies:

• Fixation: Fix mid-log phase cells with 3.7% formaldehyde for 30 minutes at room temperature.

• Cell wall digestion: Treat with zymolyase (1 mg/ml) in PEMS buffer (100 mM PIPES, 1 mM EGTA, 1 mM MgSO₄, 1.2 M sorbitol, pH 6.9) for 30 minutes at 37°C.

• Permeabilization: Incubate in PEMS with 1% Triton X-100 for 5 minutes.

• Blocking: Block with PEMBAL (PEM buffer + 1% BSA, 0.1% sodium azide, 100 mM lysine hydrochloride) for 30 minutes.

• Primary antibody: Incubate with SPBC36.02c antibody (1:50-1:200 dilution) overnight at 4°C.

• Secondary antibody: Use fluorophore-conjugated anti-rabbit IgG (1:500 dilution) for 1 hour at room temperature.

• Mounting: Mount slides with anti-fade mounting medium containing DAPI for nuclear counterstaining.

This protocol incorporates methodological approaches similar to those used for other fluorescent labeling of cellular components with antibodies .

What are common causes of false positives/negatives when using SPBC36.02c antibody, and how can they be mitigated?

Several factors can lead to false results when using SPBC36.02c antibody:

False Positives:

• Cross-reactivity with similar epitopes

• Insufficient blocking

• Excessive antibody concentration

• Non-specific binding to denatured proteins

False Negatives:

• Protein degradation during sample preparation

• Epitope masking during fixation or processing

• Insufficient antibody concentration

• Inadequate incubation time or temperature

Mitigation Strategies:

• Optimize blocking conditions (test different blockers and concentrations)

• Titrate antibody dilutions

• Include multiple controls (positive, negative, isotype controls)

• Use fresh samples and minimize protein degradation with protease inhibitors

• Vary fixation conditions if epitope accessibility is suspected

• Test alternative detection systems for improved sensitivity

These considerations align with general principles of antibody validation that emphasize rigorous controls and optimized experimental conditions .

How can SPBC36.02c antibody be validated for specificity in new experimental contexts?

To validate SPBC36.02c antibody specificity in new experimental contexts:

• Genetic validation: Compare wild-type strains with SPBC36.02c deletion or knockdown strains.

• Recombinant protein controls: Test against purified recombinant SPBC36.02c protein.

• Epitope competition: Pre-incubate antibody with immunizing peptide before application.

• Alternative antibodies: Compare results with different antibodies targeting the same protein.

• Molecular weight confirmation: Ensure detected bands match the predicted molecular weight.

• Immunoprecipitation-mass spectrometry: Confirm identity of precipitated proteins.

• Orthogonal method verification: Validate findings using complementary techniques.

This multi-faceted approach to validation is consistent with modern antibody specificity assessment methodologies that utilize multiple parameters to ensure reliable and reproducible results .

What are the optimal dilution ranges for different applications of SPBC36.02c antibody?

Based on standard practices for similar polyclonal antibodies, the following dilution ranges are recommended for SPBC36.02c antibody:

*Note: While immunofluorescence is not explicitly validated, these ranges provide starting points if researchers wish to optimize this application.

Optimization is essential as optimal dilutions may vary depending on sample type, detection method, and experimental conditions. Titration experiments should be performed to determine the ideal concentration for each specific experimental setup.

How should quantitative data from SPBC36.02c antibody experiments be normalized and analyzed?

For quantitative analysis of SPBC36.02c antibody experiments:

• Western blot densitometry:

  • Normalize band intensity to loading controls (tubulin, actin)

  • Use linear range of detection for quantification

  • Analyze with software like ImageJ or specific Western blot analysis tools

• ELISA quantification:

  • Generate standard curves using recombinant protein of known concentration

  • Ensure measurements fall within the linear range of the standard curve

  • Account for background signal from secondary antibody alone

• Statistical analysis:

  • Perform at least three biological replicates

  • Apply appropriate statistical tests based on data distribution

  • Consider using ANOVA for multiple condition comparisons

  • Report p-values and confidence intervals

• Data presentation:

  • Present normalized data as mean ± standard deviation or standard error

  • Use consistent Y-axis scales when comparing different conditions

  • Consider log transformation for wide-ranging data sets

This methodological approach ensures robust and reproducible quantification of experimental results.

How do post-translational modifications affect SPBC36.02c antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition of SPBC36.02c:

• Epitope masking: PTMs like phosphorylation, glycosylation, or ubiquitination may physically block antibody access to the epitope.

• Conformational changes: PTMs can alter protein folding, potentially exposing or hiding epitopes.

• Detection variability: Changes in PTM status across different cellular conditions may result in variable detection efficiency.

To address these issues:

• Use phosphatase or deglycosylation treatments to assess PTM effects

• Compare results across different cellular states where PTM profiles might differ

• Consider using complementary antibodies that recognize different epitopes

• For detailed PTM studies, combine immunoprecipitation with mass spectrometry

Understanding these interactions is crucial for accurate interpretation of experimental results, particularly when studying protein regulation under different physiological conditions or stress responses.

How can SPBC36.02c antibody be utilized in chromatin immunoprecipitation (ChIP) experiments?

While not specifically validated for ChIP, researchers interested in applying SPBC36.02c antibody to chromatin studies could adapt standard ChIP protocols:

• Cross-linking: Fix cells with 1% formaldehyde for 10-15 minutes at room temperature.

• Chromatin preparation: Lyse cells and sonicate to generate 200-500 bp DNA fragments.

• Immunoprecipitation: Incubate chromatin with 2-5 μg SPBC36.02c antibody overnight at 4°C.

• Protein-antibody capture: Add protein A/G beads for 2-4 hours at 4°C.

• Washing: Perform stringent washes to reduce background.

• Elution and reverse cross-linking: Elute protein-DNA complexes and reverse formaldehyde cross-links.

• DNA purification: Extract and purify DNA for downstream analysis.

• Analysis: Perform qPCR, sequencing, or microarray analysis of precipitated DNA.

Critical controls should include input DNA, IgG control, and positive/negative control regions. Optimization of antibody concentration, chromatin amount, and washing conditions is essential for successful ChIP experiments. This approach follows methodological principles similar to other antibody-based chromatin studies.

What approaches can be used to study SPBC36.02c protein-protein interactions?

To investigate SPBC36.02c protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use SPBC36.02c antibody to pull down the protein complex

  • Analyze co-precipitated proteins by mass spectrometry or Western blot

  • Perform reverse Co-IP to confirm interactions

• Proximity labeling:

  • Generate SPBC36.02c fusions with BioID or APEX2

  • Identify proteins in proximity through biotinylation followed by streptavidin pulldown

  • Analyze labeled proteins by mass spectrometry

• Yeast two-hybrid screening:

  • Use SPBC36.02c as bait to screen for interacting proteins

  • Validate identified interactions with co-IP or in vitro binding assays

• FRET/BRET analysis:

  • Create fluorescent protein fusions with SPBC36.02c and potential partners

  • Measure energy transfer to assess protein proximity in vivo

• Cross-linking mass spectrometry:

  • Cross-link protein complexes in vivo

  • Immunoprecipitate with SPBC36.02c antibody

  • Identify cross-linked peptides by mass spectrometry

These methodological approaches provide complementary data on protein-protein interactions, offering insights into SPBC36.02c function within cellular networks.

How can the SPBC36.02c antibody be adapted for super-resolution microscopy studies?

Adapting SPBC36.02c antibody for super-resolution microscopy requires special considerations:

• Secondary antibody selection:

  • Use high-quality secondary antibodies conjugated to bright, photostable fluorophores

  • For STORM/PALM: Consider secondary antibodies with Alexa Fluor 647, Cy5, or Atto dyes

  • For STED: Use STED-optimized fluorophores like Abberior STAR dyes

• Sample preparation optimization:

  • Use thinner coverslips (No. 1.5H, 170 ± 5 μm) for optimal optical properties

  • Consider embedding samples in specialized mounting media for index matching

  • For STORM/PALM: Prepare samples in oxygen-scavenging buffer systems

• Fixation considerations:

  • Test different fixatives (formaldehyde, glutaraldehyde, methanol) to preserve structure while maintaining epitope accessibility

  • Consider post-fixation with glutaraldehyde for structural stability

• Validation approaches:

  • Perform correlative imaging with conventional microscopy

  • Use dual-color imaging with known markers to validate localization patterns

  • Quantify labeling density and specificity

• Data analysis:

  • Apply drift correction and channel alignment algorithms

  • Use cluster analysis to quantify protein distribution

  • Consider 3D reconstruction for volumetric analysis

This methodological framework adapts principles from fluorescent labeling techniques to the specific challenges of super-resolution imaging with antibodies.